AstraZeneca PLC Director/PDMR Shareholding (5138U)
02 August 2022 - 2:00AM
UK Regulatory
TIDMAZN
RNS Number : 5138U
AstraZeneca PLC
01 August 2022
1 August 2022 17:00 BST
Revised stock exchange announcement due to a formatting issue
with the original announcement published at 1505 today, 1 August
2022. There have been no changes to the underlying information
within the release.
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 29 July 2022
awards of AstraZeneca American Depositary Shares (ADSs) vested to
Dr Aradhana Sarin, Executive Director and Chief Financial Officer.
Each ADS represents one half of an Ordinary Share of $0.25 in the
Company.
In accordance with the Agreement and Plan of Merger between the
Company and Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's
in-flight share awards granted by Alexion were converted to awards
over AstraZeneca ADSs under the AstraZeneca Global Restricted Stock
Plan at the time of closing of the Alexion acquisition. The awards
that vested on 29 July 2022 replaced in-flight Alexion awards
originally granted to Dr Sarin between February 2019 and February
2021 under the Alexion 2017 Incentive Plan.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, 67,523 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the
awards was US$66.72, being the closing price on the last trading
day preceding the vesting.
Further details are set out in the attached notification, made
in accordance with the requirements of the EU Market Abuse
Regulation (as it forms part of UK law pursuant to the European
Union (Withdrawal) Act 2018 .
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Aradhana Sarin
------------------------------- -----------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------- -----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name AstraZeneca PLC
------------------------------- -----------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
------------------------------- -----------------------------------------
Details of the transaction(s): section to be repeated
4i for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the AstraZeneca PLC American Depositary
financial instrument, Shares
type of instrument
Identification code CUSIP: 046353108
------------------------------- -----------------------------------------
b) Nature of the transaction Acquisition of AstraZeneca PLC American
Depository Shares pursuant to a vesting
under the Global Restricted Stock
Plan
------------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 67,523
----------
------------------------------- -----------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
------------------------------- -----------------------------------------
e) Date of the transaction 29 July 2022
------------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUAVVRUUUWRAR
(END) Dow Jones Newswires
August 01, 2022 12:00 ET (16:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024